Skip to main content
SpringerLink
Log in

Recent Advances in Breast Cancer Genetics

  • Chapter
Advances in Breast Cancer Management, Second Edition

Part of the book series: Cancer Treatment and Research ((CTAR,volume 141))

Breast cancer is the second most common cancer among women and the second leading cause of cancer death in the US. In 2006, more than 214,000 new breast cancer cases were diagnosed. It is estimated that close to 50,000 women died of the same disease in 2006. Breast cancer develops in about 12% of women who live to age 90. A positive family history is reported by 15-20% of women with breast cancer. Studies of twins suggest that heritable factors accounts for 25 to 30% of all breast cancers. However, less than 7% of all breast cancers are associated with known inherited high penetrance gene mutations. The first two major susceptibility genes for breast cancer, BRCA1 and BRCA2, were identified in 1994 and 1995, respectively. Other tumor susceptibility genes such as TP53 are known to increase breast cancer risk to an even greater level than BRCA1 and BRCA2. Nonetheless, deleterious mutations of TP53 are rare and therefore accounts for a much smaller proportion of breast cancer cases.We will review recent developments in the search for additional breast cancer susceptibility genes, recommendations for genetic counseling referral as well as follow-up of BRCA- gene mutation carriers.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abeliovich, D., L. Kaduri, I. Lerer, N. Weinberg, G. Amir, M. Sagi, J. Zlotogora, N. Heching, and T. Peretz. 1997. The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet 60:505–14.

    PubMed  CAS  Google Scholar 

  2. Antoniou, A. P. D. Pharoah, S. Narod, H. A. Risch, J. E. Eyfjord, J. L. Hopper, N. Loman, H. Olsson, O. Johannsson, A. Borg, B. Pasini, P. Radice, S. Manoukian, D. M. Eccles, N. Tang, E. Olah, H. Anton-Culver, E. Warner, J. Lubinski, J. Gronwald, B. Gorski, H. Tulinius, S. Thorlacius, H. Eerola, H. Nevanlinna, K. Syrjakoski, O.P. Kallioniemi, D. Thompson, C. Evans, J. Peto, F. Lalloo, D. G. Evans, and D.F Easton. 2003. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72:xxx–xxx.

    Article  Google Scholar 

  3. Baxter S. W., D. Y. Choong, D. M. Eccles, I. G. Campbell. 2002. Transforming Growth Factor beta Receptor 1 Polyalanine polymorphism and exon 5 mutation analysis in breast and ovarian cancer. Cancer Epidemiol Biomarkers Prev 11: 211–14.

    PubMed  CAS  Google Scholar 

  4. Berry D. A., E. S. J. Iversen, D. F. Gudbjartsson, E. H. Hiller, J. E. Garber, B. N. Peshkin, C. Lerman, P. Watson, H. T. Lynch, S. G Hilsenbeck, W. S. Rubinstein, K. S. Hughes, G. Parmigiani. 2002. BRCAPRO Validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol 20: 2701–12.

    Article  PubMed  CAS  Google Scholar 

  5. Bond GL, W. Hu, E. E. Bond, H. Robins, S. G. Lutzker, N. C. Arva, J. Bargonetti, F. Bartel, H. Taubert, P. Wuerl, K. Onel, L. Yip, S. J. Hwang, L. C. Strong, G. Lozano, A. J. Levine. 2004. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119: 591–602.

    Article  PubMed  CAS  Google Scholar 

  6. Claus E. B., N. Risch, W.D. Thompson. 1994. Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer 73: 643–51.

    Article  PubMed  CAS  Google Scholar 

  7. Daly M.B., J. E. Axilbund, E. Bryant, S. Buys, C. Eng, S. Friedman, L. J. Esserman, C. D. Farrell, J. M. Ford, J. E. Garber, J. M. Jeter, W. Kohlmann, P. M. Lynch, P. K. Marcom, L. M. Nabell, K. Offit, R. U. Osarogiagbon, B. Pasche, G. Reiser, R Sutphen, J. N. Weitzel. 2006. Genetic/Familial high-risk assessment: breast and ovarian. J Natl Compr Canc Netw 4: 156–76.

    PubMed  CAS  Google Scholar 

  8. Deng C. X. 2006. BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution. Nucleic Acids Res 34: 1416–26.

    Article  PubMed  CAS  Google Scholar 

  9. Evers B., J. Jonkers. 2006. Mouse models of BRCA1 and BRCA2 deficiency: past lessons, current understanding and future prospects. Oncogene 25: 5885–97.

    Article  PubMed  CAS  Google Scholar 

  10. FitzGerald M. G., D. J. MacDonald, M. Krainer, I. Hoover, E. O’Neil, H. Unsal, S. Silva-Arrieto, D. M. Finkelstein, P. Beer-Romero, C. Englert, D. C. Sgroi, B. L. Smith, J. W. Younger, J. E. Garber, R. B. Duda, K. A. Mayzel, K. J. Isselbacher, S. H. Friend, D. A. Haber. 1996. Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer. N Engl J Med 334: 143–49.

    Article  PubMed  CAS  Google Scholar 

  11. Frank T. S., A. M. Deffenbaugh, J. E. Reid, M. Hulick, B. E. Ward, B. Lingenfelter, K. L. Gumpper, T. Scholl, S. V. Tavtigian, D. R. Pruss, G. C. Critchfield. 2002. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10, 000 individuals. J Clin Oncol 20: 1480–90.

    Article  PubMed  CAS  Google Scholar 

  12. Genetic Testing in an Ethnically Diverse Cohort of High-Risk Women: A Comparative Analysis of BRCA1 and BRCA2 Mutations in American Families of European and African Ancestry by Nanda et al., JAMA 2005, 294: 1925–1933.

    Google Scholar 

  13. Hartmann L. C., T. A. Sellers, D. J. Schaid, T. S. Frank, C. L. Soderberg, D. L. Sitta, M. H. Frost, C. S. Grant, J. H. Donohue, J. E. Woods, S. K. McDonnell, C. W. Vockley, A Deffenbaugh, F. J. Couch, R. B. Jenkins. 2001. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 93: 1633–37.

    Article  PubMed  CAS  Google Scholar 

  14. Jemal A., R. Siegel, E. Ward, T. Murray, J. Xu, C. Smigal, M. J. Thun. 2006. Cancer statistics, 2006. Ca: a Cancer Journal for Clinicians 56: 106–30.

    Article  Google Scholar 

  15. Kaklamani V. G., L. Baddi, J. Liu, D. Rosman, S. Phukan, C. Bradley, C. Hegarty, B. McDaniel, A. Rademaker, C. Oddoux, H. Ostrer, L. S. Michel, H. Huang, Y. Chen, H. Ahsan, K. Offit, B. Pasche. 2005. Combined genetic assessment of transforming growth factor-{beta} signaling pathway variants may predict breast cancer risk. Cancer Res 65: 3454–61.

    PubMed  CAS  Google Scholar 

  16. Kaklamani V.G, Hou N., Bian Y., Reich J., Offit K., Michel LS, Rubinstein W.S., Rademaker A., Pasche B 2003. TGFBR1*6A and Cancer risk: a meta-analysis of seven case-control studies. J Clin Oncol 21: 3236–43.

    Article  PubMed  CAS  Google Scholar 

  17. Kauff N. D., J. M. Satagopan, M. E. Robson, L. Scheuer, M. Hensley, C. A. Hudis, N. A. Ellis, J. Boyd, P. I. Borgen, R. R. Barakat, L. Norton, M. Castiel, K. Nafa, K. Offit. 2002. Risk-Reducing Salpingo-oophorectomy in Women with a BRCA1 or BRCA2 Mutation. N Engl J Med 346: 1609–15.

    Article  PubMed  Google Scholar 

  18. King M. C., J. H. Marks, J. B. Mandell. 2003. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302: 643–46.

    Article  PubMed  CAS  Google Scholar 

  19. Kriege M., C. T. M. Brekelmans, C. Boetes, P. E. Besnard, H. M. Zonderland, I. M. Obdeijn, R. A. Manoliu, T. Kok, H. Peterse, M. M. A. Tilanus-Linthorst, S. H. Muller, S. Meijer, J. C. Oosterwijk, L. V. A. M. Beex, R. A. E. M. Tollenaar, H. J. de Koning, E. J. T. Rutgers, J. G. M. Klijn, the Magnetic Resonance Imaging Screening Study Group. 2004. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 351: 427–37.

    Article  PubMed  CAS  Google Scholar 

  20. Lalloo F., J. Varley, D. Ellis, A. Moran, L. O’Dair, P. Pharoah, D. G. Evans. 2003. Prediction of pathogenic mutations in patients with early-onset breast cancer by family history. Lancet 361: 1101–02.

    Article  PubMed  CAS  Google Scholar 

  21. Lichtenstein P., N. V. Holm, P. K. Verkasalo, A. Iliadou, J. Kaprio, M. Koskenvuo, E. Pukkala, A. Skytthe, K. Hemminki. 2000. Environmental and heritable factors in the causation of cancer - Analyses of cohorts of twins from Sweden, Denmark, and Finland. N E J Med 343: 78–85.

    Article  CAS  Google Scholar 

  22. Limited Family Structure and BRCA Gene Mutation Status in Single Cases of Breast Cancer JAMA, June 20, 2007; 297: 2587–2595.

    Google Scholar 

  23. Meijers-Heijboer H., B. van Geel, W. L. J. van Putten, S. C. Henzen-Logmans, C. Seynaeve, M. B. E. Menke-Pluymers, C. C. M. Bartels, L. C. Verhoog, A. M. W. van den Ouweland, M. F. Niermeijer, C. T. M. Brekelmans, J. G. M. Klijn 2001. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N E J Med 345: 159–64.

    Article  CAS  Google Scholar 

  24. Metcalfe K., H. T. Lynch, P. Ghadirian, N. Tung, I. Olivotto, E. Warner, O. I. Olopade, A. Eisen, B. Weber, J. McLennan, P. Sun, W. D. Foulkes, S. A. Narod.2004. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 22: 2328–2335.

    Article  PubMed  CAS  Google Scholar 

  25. Miki Y., J. Swensen, D. Shattuck-Eidens, P. A. Futreal, K. Harshman, S. Tavtigian, Q. Liu, C. Cochran, L. M. Bennett, W. Ding,. 1994. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266: 66–71.

    Article  PubMed  CAS  Google Scholar 

  26. Muto M. G., D. W. Cramer, J. Tangir, R. Berkowitz, S. Mok. 1996. Frequency of the BRCA1 185delAG mutation among Jewish women with ovarian cancer and matched population controls. Cancer Res 56: 1250–52.

    PubMed  CAS  Google Scholar 

  27. Narod S. A., J. S. Brunet, P. Ghadirian, M. Robson, K. Heimdal, S. L. Neuhausen, D. Stoppa-Lyonnet, C. Lerman, B. Pasini, R. P. De los, B. Weber, H. Lynch. 2000. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet 356: 1876–81.

    Article  PubMed  CAS  Google Scholar 

  28. Pasche B., P. Kolachana, K. Nafa, J. Satagopan, Y. G. Chen, R. S. Lo, D. Brener, D. Yang, L. Kirstein, C. Oddoux, H. Ostrer, P. Vineis, L. Varesco, S. Jhanwar, L. Luzzatto, J. Massague, K. Offit. 1999 T beta R-I6A is a candidate tumor susceptibility allele. Cancer Res 59: 5678–82.

    PubMed  CAS  Google Scholar 

  29. Pasche B., Y. Luo, P. H. Rao, S. D. Nimer, E. Dmitrovsky, P. Caron, L. Luzzatto, K. Offit, C. Cordon-Cardo, B. Renault, J. M. Satagopan, V. V. Murty, J. Massague. 1998. Type I transforming growth factor beta receptor maps to 9q22 and exhibits a polymorphism and a rare variant within a polyalanine tract. Cancer Res 58: 2727–32.

    PubMed  CAS  Google Scholar 

  30. Pasche B., T. J. Knobloch, Y. Bian, J. Liu, S. Phukan, D. Rosman, V. Kaklamani, L. Baddi, F. S. Siddiqui, W. Frankel, T. W. Prior, D. E. Schuller, A. Agrawal, J. Lang, M. E. Dolan, E. E. Vokes, W. S. Lane, C. C. Huang, T. Caldes, A. Di Cristofano, H. Hampel, I. Nilsson, G. von Heijne, R. Fodde, V. V. V. S. Murty, A. de la Chapelle, C. M. Weghorst. 2005. Somatic acquisition and signaling of TGFBR1*6A in cancer. JAMA294: 1634–46.

    Article  PubMed  CAS  Google Scholar 

  31. Pharoah P. D., A. Antoniou, M. Bobrow, R. L. Zimmern, D. F. Easton, B. A. Ponder. 2002. Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet 31: 33–6.

    Article  PubMed  CAS  Google Scholar 

  32. Phillips K. A., M. A. Jenkins, G. J. Lindeman, S. A. McLachlan, J. M. McKinley, P. C. Weideman, J. L. Hopper, M. L. Friedlander. 2006. Risk-reducing Surgery, Screening and Chemoprevention practices of Brcai and BRCA2 mutation carriers: A prospective cohort study, Clinical Genetics 70: 198–206.

    Article  PubMed  Google Scholar 

  33. Pierce D. F., Jr., A. E. Gorska, A. Chytil, K. S. Meise, D. L. Page, R. J. Coffey, Jr., H. L. Moses. 1995. Mammary tumor suppression by transforming growth factor beta 1 transgene expression. Proc Natl Acad Sci U S A 92: 4254–58.

    Article  PubMed  CAS  Google Scholar 

  34. Rebbeck T. R., T. Friebel, H. T. Lynch, S. L. Neuhausen, L. ‘t Veer, J. E. Garber, G. R. Evans, S. A. Narod, C. Isaacs, E. Matloff, M. B. Daly, O. I. Olopade, B. L. Weber. 2004. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: The PROSE Study Group. J Clin Oncol 22: 1055–62.

    Article  PubMed  Google Scholar 

  35. Rebbeck T. R., H. T. Lynch, S. L. Neuhausen, S. A. Narod, L. van’t Veer, J. E. Garber, G. Evans, C. Isaacs, M. B. Daly, E. Matloff, O. I. Olopade, B. L. Weber, the Prevention and Observation of Surgical End Points Study Group. 2002. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346: 1616–22.

    Article  PubMed  Google Scholar 

  36. ShattuckEidens D., M. Mcclure, J. Simard, F. Labrie, S. Narod, F. Couch, K. Hoskins, B. Weber, L. Castilla, M. Erdos, L. Brody, L. Friedman, E. Ostermeyer, C. Szabo, M. C. King, S. Jhanwar, K. Offit, L. Norton, T. Gilewski, M. Lubin, M. Osborne, D. Black, M. Boyd, M. Steel, S. Ingles, R. Haile, A. Lindblom, H. Olsson, A. Borg, D. T. Bishop, E. Solomon, P. Radice, G. Spatti, S. Gayther, B. Ponder, W. Warren, M. Stratton, Q. Y. Liu, F. Fujimura, C. Lewis, M. H. Skolnick, D. E. Goldgar. 1995. A collaborative survey of 80 mutations in the brca1 breast-cancer and ovarian-cancer susceptibility gene - implications for presymptomatic testing and screening. JAMA 273: 535–41.

    Article  CAS  Google Scholar 

  37. Struewing J. P., P. Hartge, S. Wacholder, S. M. Baker, M. Berlin, M. McAdams, M. M. Timmerman, L. C. Brody, M. A. Tucker. 1997. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews [see comments]. N E J Med 336: 1401–08.

    Article  CAS  Google Scholar 

  38. Walsh T., S. Casadei, K. H. Coats, E. Swisher, S. M. Stray, J. Higgins, K. C. Roach, J. Mandell, M. K. Lee, S. Ciernikova, L. Foretova, P. Soucek, M. C. King. 2006. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 295: 1379–88.

    Article  PubMed  CAS  Google Scholar 

  39. Warner E., W. Foulkes, P. Goodwin, W. Meschino, J. Blondal, C. Paterson, H. Ozcelik, P. Goss, D. lingham-Hawkins, N. Hamel, P. L. Di, V. Contiga, C. Serruya, M. Klein, R. Moslehi, J. Honeyford, A. Liede, G. Glendon, J. S. Brunet, S. Narod. 1999. Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. J Natl Cancer Inst 91: 1241–47.

    Article  PubMed  CAS  Google Scholar 

  40. Wideroff L., S. T. Vadaparampil, N. Breen, R. T. Croyle, A. N. Freedman. 2003. Awareness of genetic testing for increased cancer risk in the year 2000 National Health Interview Survey. Community Genet 6: 147–56.

    Article  PubMed  Google Scholar 

  41. Wooster R., G. Bignell, J. Lancaster, S. Swift, S. Seal, J. Mangion, N. Collins, S. Gregory, C. Gumbs, G. Micklem, R. Barfoot, R. Hamoudi, S. Patel, C. Rice, P. Biggs, Y. Hashim, A. Smith, F. Connor, A. Arason, J. Gudmundsson, D. Ficenec, D. Kelsell, D. Ford, P. Tonin, D. T. Bishop, N. K. Spurr, B. A. J. Ponder, R. Eeles, J. Peto, P. Devilee, C. Cornelisse, H. Lynch, S. Narod, G. Lenoir, V. Egilsson, R. B. Barkadottir, D. F. Easton, D. R. Bentley, P. A. Futreal, A. Ashworth, M. R. Stratton. 1995. Identification of the breast-cancer susceptibility gene Brca2. Nature 378: 789–92.

    Article  PubMed  CAS  Google Scholar 

  42. Yoshida K., Y. Miki. 2004. Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage. Cancer Sci 95: 866–71.

    Article  PubMed  CAS  Google Scholar 

  43. Zhang HT, J. Zhao, S. Y. Zheng, X. F. Chen. 2005. Is TGFBR1*6A really associated with increased risk of cancer? J Clin Oncol 23: 7743–44.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Robert H. Lurie Comprehensive Cancer Center, Northwestern University School of Medicine, 675 North St, 60611, Chicago, IL, USA

    Boris Pasche M.D., PhD, F.A.C.P

Authors
  1. Boris Pasche M.D., PhD, F.A.C.P
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Northwestern University School of Medicine, 675 North St, 60611, Chicago, IL, USA

    William J. Gradishar M.D.

  2. Emory University School of Medicine, 201 Dowman Drive, 30322, Atlanta, GA, USA

    William C. Wood M.D.

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Pasche, B. (2008). Recent Advances in Breast Cancer Genetics. In: Gradishar, W.J., Wood, W.C. (eds) Advances in Breast Cancer Management, Second Edition. Cancer Treatment and Research, vol 141. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-73161-2_1

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-73161-2_1

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-387-73160-5

  • Online ISBN: 978-0-387-73161-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation